Black Diamond Therapeutics
BDTX
88 hedge funds and large institutions have $200M invested in Black Diamond Therapeutics in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 24 increasing their positions, 22 reducing their positions, and 14 closing their positions.
376% more call options, than puts
Call options by funds: $243K | Put options by funds: $51K
87% more capital invested
Capital invested by funds: $107M → $200M (+$92.8M)
86% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 14
16% more funds holding
Funds holding: 76 → 88 (+12)
2.4% more ownership
Funds ownership: 73.84% → 76.24% (+2.4%)
9% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$11.3M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$3.54M |
| 3 |
Millennium Management
New York
|
+$1.71M |
| 4 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$1.27M |
| 5 |
Goldman Sachs
New York
|
+$1.16M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
-$4.94M |
| 2 |
AG
Artal Group
Luxembourg
|
-$4.03M |
| 3 |
JP Morgan Chase
New York
|
-$3.27M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$1.56M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.52M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Fidelity Investments
Boston,
Massachusetts
| – | -$6 | -2 | Closed |
|
BDTX Hedge Fund Activity: Q1 2024 in Review
88 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2024, worth a combined $200M — up 87% from $107M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new BDTX positions and 14 closed out — a net gain of 12 holders — while 24 added to existing stakes and 22 trimmed.
The largest buyer was T. Rowe Price Investment Management, adding an estimated $11.3M. The largest seller was Verition Fund Management, cutting an estimated $4.94M.
- 88 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2024, up from 76 in Q4 2023.
- Funds reported $200M of Black Diamond Therapeutics stock for Q1 2024, up 87% quarter-over-quarter.
- 26 funds opened new Black Diamond Therapeutics positions in Q1 2024 and 14 closed out, a net change of +12 holders.
- The largest Black Diamond Therapeutics buyer in Q1 2024 was T. Rowe Price Investment Management, an estimated $11.3M added.
- The largest Black Diamond Therapeutics seller in Q1 2024 was Verition Fund Management, an estimated $4.94M sold.
Based on aggregated 13F filings for Q1 2024.